Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, September 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 30 news outlets
blogs: 3 blogs
twitter: 169 X users
video: 1 YouTube creator

guideline: 4 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 4 podcasts

Readers on

mendeley: 228 Mendeley

So far, Altmetric has seen 47 news stories from 30 outlets.

Richard Cathomas on Added BCG for High-Risk Muscle-Invasive Bladder Cancer

MedPage Today, 01 Oct 2026

This Reading Room is a collaboration between MedPage Today® and: The use of intravesical Bacillus Calmette-Guérin (BCG) vaccine…

Bladder Cancer Care Is Entering a New Era Medscape News EuropeAugust 11, 2026

Medscape, 11 Aug 2026

The diagnosis of bladder cancer relies on a combination of clinical evaluation, laboratory testing, imaging, endoscopy, and…

Durvalumab: nuove indicazioni in polmone, vescica ed endometrio

Scienza e Farmici, 29 Jun 2026

L’Agenzia Italiana del Farmaco (Aifa) ha approvato la rimborsabilità di durvalumab in nuovi setting di trattamento.

Muskelinvasives Harnblasenkarzinom: Mit rekombinantem BCG die Ergebnisse verbessern? – Deutsches Ärzteblatt

Deutsches Ärzteblatt, 22 Jun 2026

News Medizin Muskelinvasives Harnblasenkarzinom: Mit rekombinantem BCG die Ergebnisse verbessern? Medizin Montag, 22.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 43 additional news stories.